-
News | 2020.11.09
Leptospirosis: elucidation of a new gene regulation mechanism based on DNA modification
Pathogenic Leptospira are responsible for leptospirosis, a disease that occurs in many world regions. Leptospirosis is a zoonosis, in other words it affects wild or domestic animals but may be transmitted to humans. A partnership between the Institut Pasteur (Paris) and the INRS Armand-Frappier Santé Biotechnologie Research Center has led to the discovery of a novel mechanism for virulence...
-
News | 2020.10.22
Coronavirus: Institut Pasteur warns against false information circulating on social media
-ENGLISH VERSION COMING SOON-Mis à jour le 20 mars 2023.En 2020-2021, lorsque la pandémie de Covid-19 était à son pic, de nombreuses informations circulaient dans les médias, sur les réseaux sociaux, les messageries instantanées, etc. Ces messages ont pu parfois contenir des informations erronées ou s’appuyant sur des propos attribués à tort à des chercheurs de l’Institut Pasteur à...
-
Document de presse | 2020.10.16
Team of international scientists identify common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses
Driven by Molecular Insights, Massive Analysis of Medical Records from ~740,000 SARS-CoV-2 Patients Reveal Treatment Regimens for Current, and Potential Future, Viral Pandemics. Published on October 15, 2020, in Science. In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the...
-
Article | 2020.10.14
Covid-19: A vaccine candidate using a lentiviral vector
This vaccine candidate for the SARS-CoV-2 virus, designed for nasal administration, demonstrated intense protection and extremely high production of antibodies and cytotoxic cell responses in preclinical trials.
-
News | 2020.08.04
Malaria: parasite resistance to artemisinin now found in Africa
Resistance to artemisinin, the main component of current antimalarial treatments recommended by WHO, is widespread in South-East Asia, but has not been described in Africa. In a study published in 2020, scientists from the Institut Pasteur, in collaboration with the NMCP in Rwanda, the WHO and Columbia University provided for the first time evidence of the de novo emergence of Pfkelch13-mediated...
-
News | 2020.07.27
A new biotechnology tool to tackle antibiotic resistance
Designing effective new molecules to tackle infectious diseases is a difficult process that currently represents a huge challenge for scientists, especially given the rise in bacterial resistance to antibiotics. Scientists from the Institut Pasteur's Bacterial Genome Plasticity Unit have responded to this challenge by developing a new biotechnological tool which bypasses the sampling limitations...
-
Article | 2020.06.22
Developing a rapid diagnostic test to detect SARS-CoV2 virus in various environment
Aim: The epidemy of the SARS-CoV-2 virus and its global spread urgently requires efficient means for rapid diagnosis, as well as detection in various environments (aside from clinical laboratories), such as airplanes, schools, potential animal carriers, etc. We have previously devised a colorimetric method to detect specific pathogen sequences using Rolling Circle Amplification (RCA) which...
-
Article | 2020.06.16
Evolution of SARS-CoV-2 and the antibody immune response in humans during infection
Aim: to understand the evolution of the SARS-CoV-2 viral population in hosts during illness, in relation with the infectivity of the virus and the establishment of the humoral (antibody-based) immune response. This knowledge is important to identify trends in disease progression and help improve the treatment and post-treatment follow-up given to patients. Detailed data on the evolution of...
-
Document de presse | 2020.05.26
COVID-19: the vast majority of patients with a minor form develop neutralizing antibodies
Teams from Strasbourg University Hospital and the Institut Pasteur carried out a study among hospital staff on the two sites of Strasbourg University Hospital. After observing 160 people with minor forms of COVID-19, the scientists concluded that nearly all the patients developed antibodies within two weeks of being infected. In 98% of the patients, neutralizing antibodies were detected after 28...
-
News | 2020.05.14
LuLISA project, bioluminescence as a tool for human diagnostics, from allergy to Covid19
The LuLISA (Luciferase-Linked ImmunoSorbent Assay) research project aims developing high throughput serological tests for epidemiological studies at local, regional or nation scales. In a recent scientific publication, concerning the detection and dosing of IgE specific to several allergens in patients’ blood samples, the use of LuLISA proves to be a vastly improved detection method in...